File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO)
  • Basic View
  • Metadata View
  • XML View
TitleA case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO)
 
AuthorsYau, T1
Leong, CH
Chan, WK3
Chan, JK2
Liang, RHS1
Epstein, RJ1
 
KeywordsAdult Wilm's tumour
Angiosarcoma
Drug therapy
 
Issue Date2008
 
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
 
CitationCancer Chemotherapy And Pharmacology, 2008, v. 61 n. 4, p. 717-720 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s00280-007-0529-1
 
AbstractHere we report an unusual case of mixed Wilms' tumour and angiosarcoma in a 38-year-old female patient who presented with haematuria and right lower back pain. A computed tomographic (CT) scan confirmed a massive renal tumour associated with extensive retroperitoneal lymph node involvement, bony metastases and a right hip fracture. She was initially managed with palliative nephrectomy, which was followed by rapid postoperative deterioration. Histopathology revealed differentiated adult Wilms' tumour with renal angiosarcoma, whereas the pathology of the para-aortic lymph node and bone metastasis revealed angiosarcoma only. In view of her cachexia and cytopaenia, emergency chemotherapy was initiated using a modified regimen of carboplatin, etoposide and vincristine (CEO) in preference to the more traditional but less well-tolerated VAC (vincristine, actinomycin D, cyclophosphamide). Four cycles of this protocol yielded a dramatic response on re-staging CT scan. This case suggests that highly angiogenic tumours such as angiosarcoma may be effectively palliated using agents usually reserved for refractory Wilms' tumour, and supports the view that adult Wilms' tumour is more sensitive to such agents. © 2007 Springer-Verlag.
 
ISSN0344-5704
2012 Impact Factor: 2.795
2012 SCImago Journal Rankings: 0.904
 
DOIhttp://dx.doi.org/10.1007/s00280-007-0529-1
 
ISI Accession Number IDWOS:000252222900022
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorYau, T
 
dc.contributor.authorLeong, CH
 
dc.contributor.authorChan, WK
 
dc.contributor.authorChan, JK
 
dc.contributor.authorLiang, RHS
 
dc.contributor.authorEpstein, RJ
 
dc.date.accessioned2011-03-28T09:27:28Z
 
dc.date.available2011-03-28T09:27:28Z
 
dc.date.issued2008
 
dc.description.abstractHere we report an unusual case of mixed Wilms' tumour and angiosarcoma in a 38-year-old female patient who presented with haematuria and right lower back pain. A computed tomographic (CT) scan confirmed a massive renal tumour associated with extensive retroperitoneal lymph node involvement, bony metastases and a right hip fracture. She was initially managed with palliative nephrectomy, which was followed by rapid postoperative deterioration. Histopathology revealed differentiated adult Wilms' tumour with renal angiosarcoma, whereas the pathology of the para-aortic lymph node and bone metastasis revealed angiosarcoma only. In view of her cachexia and cytopaenia, emergency chemotherapy was initiated using a modified regimen of carboplatin, etoposide and vincristine (CEO) in preference to the more traditional but less well-tolerated VAC (vincristine, actinomycin D, cyclophosphamide). Four cycles of this protocol yielded a dramatic response on re-staging CT scan. This case suggests that highly angiogenic tumours such as angiosarcoma may be effectively palliated using agents usually reserved for refractory Wilms' tumour, and supports the view that adult Wilms' tumour is more sensitive to such agents. © 2007 Springer-Verlag.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationCancer Chemotherapy And Pharmacology, 2008, v. 61 n. 4, p. 717-720 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s00280-007-0529-1
 
dc.identifier.doihttp://dx.doi.org/10.1007/s00280-007-0529-1
 
dc.identifier.epage720
 
dc.identifier.hkuros131216
 
dc.identifier.isiWOS:000252222900022
 
dc.identifier.issn0344-5704
2012 Impact Factor: 2.795
2012 SCImago Journal Rankings: 0.904
 
dc.identifier.issue4
 
dc.identifier.pmid17571263
 
dc.identifier.scopuseid_2-s2.0-38049008451
 
dc.identifier.spage717
 
dc.identifier.urihttp://hdl.handle.net/10722/132659
 
dc.identifier.volume61
 
dc.languageeng
 
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
 
dc.publisher.placeGermany
 
dc.relation.ispartofCancer Chemotherapy and Pharmacology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdult
 
dc.subject.meshAntineoplastic Agents - administration & dosage
 
dc.subject.meshAntineoplastic Agents, Phytogenic - administration & dosage
 
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - administration & dosage - adverse effects - therapeutic use
 
dc.subject.meshCarboplatin - administration & dosage
 
dc.subject.meshCombined Modality Therapy
 
dc.subject.meshEtoposide - administration & dosage
 
dc.subject.meshFatal Outcome
 
dc.subject.meshFemale
 
dc.subject.meshHemangiosarcoma - drug therapy - pathology - surgery
 
dc.subject.meshHumans
 
dc.subject.meshKidney Neoplasms - drug therapy - pathology - surgery
 
dc.subject.meshMagnetic Resonance Imaging
 
dc.subject.meshNeoplasm Metastasis
 
dc.subject.meshNeoplasm Recurrence, Local
 
dc.subject.meshPlatelet Count
 
dc.subject.meshTomography, X-Ray Computed
 
dc.subject.meshVincristine - administration & dosage
 
dc.subject.meshWilms Tumor - drug therapy - pathology - surgery
 
dc.subjectAdult Wilm's tumour
 
dc.subjectAngiosarcoma
 
dc.subjectDrug therapy
 
dc.titleA case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO)
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yau, T</contributor.author>
<contributor.author>Leong, CH</contributor.author>
<contributor.author>Chan, WK</contributor.author>
<contributor.author>Chan, JK</contributor.author>
<contributor.author>Liang, RHS</contributor.author>
<contributor.author>Epstein, RJ</contributor.author>
<date.accessioned>2011-03-28T09:27:28Z</date.accessioned>
<date.available>2011-03-28T09:27:28Z</date.available>
<date.issued>2008</date.issued>
<identifier.citation>Cancer Chemotherapy And Pharmacology, 2008, v. 61 n. 4, p. 717-720</identifier.citation>
<identifier.issn>0344-5704</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/132659</identifier.uri>
<description.abstract>Here we report an unusual case of mixed Wilms&apos; tumour and angiosarcoma in a 38-year-old female patient who presented with haematuria and right lower back pain. A computed tomographic (CT) scan confirmed a massive renal tumour associated with extensive retroperitoneal lymph node involvement, bony metastases and a right hip fracture. She was initially managed with palliative nephrectomy, which was followed by rapid postoperative deterioration. Histopathology revealed differentiated adult Wilms&apos; tumour with renal angiosarcoma, whereas the pathology of the para-aortic lymph node and bone metastasis revealed angiosarcoma only. In view of her cachexia and cytopaenia, emergency chemotherapy was initiated using a modified regimen of carboplatin, etoposide and vincristine (CEO) in preference to the more traditional but less well-tolerated VAC (vincristine, actinomycin D, cyclophosphamide). Four cycles of this protocol yielded a dramatic response on re-staging CT scan. This case suggests that highly angiogenic tumours such as angiosarcoma may be effectively palliated using agents usually reserved for refractory Wilms&apos; tumour, and supports the view that adult Wilms&apos; tumour is more sensitive to such agents. &#169; 2007 Springer-Verlag.</description.abstract>
<language>eng</language>
<publisher>Springer. The Journal&apos;s web site is located at http://www.springer.com/medicine/oncology/journal/280</publisher>
<relation.ispartof>Cancer Chemotherapy and Pharmacology</relation.ispartof>
<subject>Adult Wilm&apos;s tumour</subject>
<subject>Angiosarcoma</subject>
<subject>Drug therapy</subject>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Antineoplastic Agents - administration &amp; dosage</subject.mesh>
<subject.mesh>Antineoplastic Agents, Phytogenic - administration &amp; dosage</subject.mesh>
<subject.mesh>Antineoplastic Combined Chemotherapy Protocols - administration &amp; dosage - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>Carboplatin - administration &amp; dosage</subject.mesh>
<subject.mesh>Combined Modality Therapy</subject.mesh>
<subject.mesh>Etoposide - administration &amp; dosage</subject.mesh>
<subject.mesh>Fatal Outcome</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Hemangiosarcoma - drug therapy - pathology - surgery</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Kidney Neoplasms - drug therapy - pathology - surgery</subject.mesh>
<subject.mesh>Magnetic Resonance Imaging</subject.mesh>
<subject.mesh>Neoplasm Metastasis</subject.mesh>
<subject.mesh>Neoplasm Recurrence, Local</subject.mesh>
<subject.mesh>Platelet Count</subject.mesh>
<subject.mesh>Tomography, X-Ray Computed</subject.mesh>
<subject.mesh>Vincristine - administration &amp; dosage</subject.mesh>
<subject.mesh>Wilms Tumor - drug therapy - pathology - surgery</subject.mesh>
<title>A case of mixed adult Wilms&apos; tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO)</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1007/s00280-007-0529-1</identifier.doi>
<identifier.pmid>17571263</identifier.pmid>
<identifier.scopus>eid_2-s2.0-38049008451</identifier.scopus>
<identifier.hkuros>131216</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-38049008451&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>61</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>717</identifier.spage>
<identifier.epage>720</identifier.epage>
<identifier.isi>WOS:000252222900022</identifier.isi>
<publisher.place>Germany</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Queen Elizabeth Hospital Hong Kong
  3. Hong Kong Sanatorium and Hospital